↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 10: Endocannabinoids
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

twitter
10 tweeters
facebook
7 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
169 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids
Chapter number 10
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_10
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

Katona, István, István Katona, István Katona Ph.D.

Editors

Roger G. Pertwee

Abstract

The antiepileptic potential of Cannabis sativa preparations has been historically recognized. Recent changes in legal restrictions and new well-documented cases reporting remarkably strong beneficial effects have triggered an upsurge in exploiting medical marijuana in patients with refractory epilepsy. Parallel research efforts in the last decade have uncovered the fundamental role of the endogenous cannabinoid system in controlling neuronal network excitability raising hopes for cannabinoid-based therapeutic approaches. However, emerging data show that patient responsiveness varies substantially, and that cannabis administration may sometimes even exacerbate seizures. Qualitative and quantitative chemical variability in cannabis products and personal differences in the etiology of seizures, or in the pathological reorganization of epileptic networks, can all contribute to divergent patient responses. Thus, the consensus view in the neurologist community is that drugs modifying the activity of the endocannabinoid system should first be tested in clinical trials to establish efficacy, safety, dosing, and proper indication in specific forms of epilepsies. To support translation from anecdote-based practice to evidence-based therapy, the present review first introduces current preclinical and clinical efforts for cannabinoid- or endocannabinoid-based epilepsy treatments. Next, recent advances in our knowledge of how endocannabinoid signaling limits abnormal network activity as a central component of the synaptic circuit-breaker system will be reviewed to provide a framework for the underlying neurobiological mechanisms of the beneficial and adverse effects. Finally, accumulating evidence demonstrating robust synapse-specific pathophysiological plasticity of endocannabinoid signaling in epileptic networks will be summarized to gain better understanding of how and when pharmacological interventions may have therapeutic relevance.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 169 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Romania 1 <1%
Unknown 168 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 38 22%
Researcher 24 14%
Student > Ph. D. Student 23 14%
Student > Master 21 12%
Other 15 9%
Other 24 14%
Unknown 24 14%
Readers by discipline Count As %
Medicine and Dentistry 44 26%
Agricultural and Biological Sciences 19 11%
Neuroscience 16 9%
Pharmacology, Toxicology and Pharmaceutical Science 11 7%
Biochemistry, Genetics and Molecular Biology 11 7%
Other 32 19%
Unknown 36 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2018.
All research outputs
#2,796,872
of 17,906,477 outputs
Outputs from Handbook of experimental pharmacology
#94
of 535 outputs
Outputs of similar age
#51,267
of 272,023 outputs
Outputs of similar age from Handbook of experimental pharmacology
#1
of 2 outputs
Altmetric has tracked 17,906,477 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 535 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,023 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them